Capricor Shares Crash 60% as FDA Panel Rejects Duchenne Therapy Data

Key Facts

In a move reflecting the high sensitivity of the biotech sector to regulatory decisions, Capricor Therapeutics faced a major setback. The company's shares plunged nearly 60% in premarket trading on Thursday following a negative ruling from a U.S. FDA advisory panel. This crash occurred after experts voted against the effectiveness data of the company's lead cell therapy candidate for Duchenne muscular dystrophy-related heart conditions.

The panel's rejection creates a significant regulatory hurdle for the therapy's approval, severely impacting investor confidence in the company's pipeline. According to analyst reports, the 60% drop is a major reaction to clinical failure, although the event was partially anticipated by prior market warnings regarding the regulatory path for this specific treatment.

On the broader economic front, the market awaits U.S. Durable Goods Orders on July 27, which may influence general risk appetite for small and mid-cap biotech firms.